問卷

TPIDB > Search Result

Search Result

篩選

List

11Cases

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Infusion fluid Infusion fluid Tablets

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-07-22 - 2026-12-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-06-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-10-01 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-09-01 - 2026-08-31

Phase IV

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-01-31 - 2026-06-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2024-09-30 - 2028-11-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-08-01 - 2028-01-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

1 2